Eugit Therapeutics
Eugit Therapeutics, co-founded by George Church and based in California, specializes in developing targeted therapies for inflammatory diseases using its proprietary TAGHOME technology.
Company Overview
Eugit Therapeutics, previously known as EUGIT Tx and EUGIT Therapeutics, is located in San Carlos, CA, and South San Francisco, CA, USA. This healthcare company operates within the drug discovery and delivery sub-industry. Eugit Therapeutics aims to enhance drug safety and efficacy through their cutting-edge TAGHOME technology, which delivers drugs with precision to diseased tissues using T cell receptors.
Healthcare Solutions
Eugit Therapeutics targets non-specific drugs responsible for toxicity and clinical trial failures, thereby addressing tissue-specific inflammatory diseases that affect millions. Their innovative TAGHOME technology offers tissue-targeting therapies designed to improve safety and efficacy, focusing initially on the 3.1 million U.S. individuals with Inflammatory Bowel Disease. The company is in the early stages of development and plans to start clinical trials within two years.
Founders and Key People
Eugit Therapeutics was co-founded by George Church, a prominent figure from Harvard. The company is backed by Y Combinator, having participated in the S22 batch. Despite having a small team size of 2, the company leverages expertise from fields such as Cell Therapy, Synthetic Biology, Therapeutics, Oncology, and Biotechnology.
Funding and Support
Eugit Therapeutics received funding and support from Y Combinator, joining their Summer 2022 (S22) batch. This involvement has provided them with essential resources and mentorship to drive their mission forward. The company aims to transform drug delivery methods and foster breakthroughs in the healthcare industry.
Locations and Operational Reach
Eugit Therapeutics operates out of San Carlos, CA, and South San Francisco, CA, USA. Their geographical focus covers the United States and extends to the broader regions of America and Canada. This regional focus aligns with their initial aim of addressing healthcare needs for the millions affected by tissue-specific inflammatory diseases in these areas.
